| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-06-24 |
| タイトル |
|
|
タイトル |
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302) |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
inflammatory marker |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
multicenter study |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nanoliposomal irinotecan |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
pancreatic cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
retrospective studies |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Araki, Tomonori
Hayashi, Kohei
Shimokawa, Mototsugu
Otsuka, Taiga
Sonoda, Yuki
Honda, Takuya
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Komori, Azusa
Otsu, Satoshi
Hosokawa, Ayumu
Sakai, Tatsunori
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Taguchi, Hiroki
Tsuneyoshi, Kengo
Fujita, Toshihiro
Sakae, Takahiro
Kawaguchi, Yasunori
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Relationships between cancer onset, progression, and inflammation have been reported; yet, the significance of inflammatory markers before and after treatment with nanoliposomal irinotecan and fluorouracil with folic acid (NFF) is unclear. Objectives: We aimed to (1) investigate whether worsening inflammation is associated with disease progression and whether it can be used as a biomarker by comparing inflammatory markers before and after treatment with NFF and (2) verify which is a superior biomarker. Design: This was a preplanned analysis of a retrospective cohort of the NAPOLEON-2 study, a multicenter observational study. Patients from 20 institutions were enrolled. Those with unresectable pancreatic cancer who received NFF as a second-line or later-line treatment between June 1, 2020, and May 31, 2021, were included. Methods: The primary endpoint was overall survival, and the main secondary endpoint was progression-free survival. The following inflammatory markers were assessed: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, Prognostic Nutrition Index (PNI), C-reactive protein/albumin ratio (CAR), Glasgow prognostic score (GPS), Prognostic Index (PI), and Komori score. Results: A total of 161 patients were enrolled. The CAR, NLR, GPS (1 vs 2), PI (1 vs 2), PNI, and Komori score were useful pre-NFF biomarkers (hazard ratios (HRs): 2.59, 2.28, 2.76/3.35, 2.16/18.89, 2.13, and 3.39, respectively). The CAR, NLR, GPS (compared with a score of 1/2), and PI (compared with a score of 1/2) were useful post-NFF biomarkers (HRs: 2.63, 1.88, 2.54/3.09, 2.30/5.39, respectively). In terms of the receiver operating characteristic curve and Akaike information criterion, the CAR, GPS, and PI showed favorable trends, and overall, CAR was a useful biomarker. Conclusion: Inflammatory markers can be used as biomarkers both before and after NFF treatment, and CAR may be useful. We hope these findings will contribute to the selection of appropriate treatment options. |
|
言語 |
en |
| 書誌情報 |
en : Therapeutic Advances in Medical Oncology
巻 17,
p. 1-14,
発行日 2025-02-21
|
| 出版者 |
|
|
出版者 |
SAGE Publications Inc |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1758-8359 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1177/17588359251320768 |
| 権利 |
|
|
権利情報 |
© The Author(s), 2025. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Therapeutic Advances in Medical Oncology, 17, pp.1-14; 2025 |
|
言語 |
en |
TAMO17_1.pdf (1.5 MB)
